Vantage logo

Go or no go? A first for Nefecon

Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.